Relevant Interviews, Disease and Trial Updates and Stock-Markets News posted by CRISPR Medicine News.

Check also Companies to Follow in 2022 and CMN Markets for the latest stock and market trends.

Always stay updated with the free CMN Newsletter.


Main focus: Treatment of bacterial infections

Company stage: Pre-clinical

Diseases: Bloodstream infections caused by E. coli, other infections

Genome editing tool: CRISPR-Cas

Funding stage: Private

Location: Copenhagen, Denmark


Partners: Novo Nordisk

SNIPR Biome is a Danish, pre-clinical stage company. The company is focused on novel CRISPR-based antibacterial therapies. The company has patents on several CRISPR-Cas technologies including the Cas9, Cas3 and Cas12a enzymes. While SNIPR Biome has not revealed an official pipeline, it has disclosed the use of its DNA-based CRISPR-guided vector platform to generate next-generation antibiotic therapies.


HashtagSNIPR Biome

Company: SNIPR Biome
Jobs, banner ads, webinars, sponsored content...
Search CRISPR Medicine